Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer

Deep learning identifies morphological features in breast cancer predictive of cancer ERBB2 status and trastuzumab treatment efficacy

(2021) Dmitrii Bychkov et al.   Scientific Reports

Re-epithelialization and immune cell behaviour in an ex vivo human skin model

(2020) Ana Rakita et al.   Scientific Reports

The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups

(2020) Ji Won Woo et al.   HUMAN PATHOLOGY

Emerging role of deep learning‐based artificial intelligence in tumor pathology

(2020) Yahui Jiang et al.   Cancer Communications

Deep learning-enabled breast cancer hormonal receptor status determination from base-level H&E stains

(2020) Nikhil Naik et al.   Nature Communications

Deep learning-based cross-classifications reveal conserved spatial behaviors within tumor histological images

(2020) Javad Noorbakhsh et al.   Nature Communications

HER2 and Breast Cancer — A Phenomenal Success Story

(2019) Daniel F. Hayes   NEW ENGLAND JOURNAL OF MEDICINE

Predicting gene regulatory interactions based on spatial gene expression data and deep learning

(2019) Yang Yang et al.   PLoS Computational Biology

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

(2018) Antonio C. Wolff et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Predicting cancer outcomes from histology and genomics using convolutional networks

(2018) Pooya Mobadersany et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning

(2018) Nicolas Coudray et al.   NATURE MEDICINE

Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer

(2017) Hope S. Rugo et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy

(2017) Ander Urruticoechea et al.   JOURNAL OF CLINICAL ONCOLOGY

Stain Deconvolution Using Statistical Analysis of Multi-Resolution Stain Colour Representation

(2017) Najah Alsubaie et al.   PLoS One

HER2 testing and its predictive utility in anti-HER2 breast cancer therapy

(2015) Pooja P Advani et al.   Biomarkers in Medicine

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

(2013) Luca Gianni et al.   JOURNAL OF CLINICAL ONCOLOGY

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

(2010) Kimberly L. Blackwell et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients WithHER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens

(2010) Vicente Valero et al.   JOURNAL OF CLINICAL ONCOLOGY